Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30920216 | 1.00 | IKBKB (0.32) | IKBKBSMN1; SMN2MAPK1NOX1SCD | |
| SCHEMBL30920200 | 1.00 | IKBKB (0.32) | IKBKBSMN1; SMN2MAPK1NOX1SCD | |
| SCHEMBL27247200 | 0.90 | IKBKB (0.33) | IKBKBSMN1; SMN2MAPK1NOX1SCD | |
| SCHEMBL30920755 | 0.89 | IKBKB (0.32) | IKBKBSMN1; SMN2MAPK1NOX1SCD | |
| SCHEMBL30920788 | 0.89 | NPC1 (0.34) | IKBKBSMN1; SMN2MAPK1NOX1SCD | |
| SCHEMBL27247307 | 0.89 | IKBKB (0.32) | IKBKBSMN1; SMN2MAPK1NOX1SCD | |
| SCHEMBL30920544 | 0.89 | SMN1; SMN2 (0.35) | IKBKBSMN1; SMN2MAPK1NOX1SCD | |
| SCHEMBL27247703 | 0.89 | NPC1 (0.34) | IKBKBSMN1; SMN2MAPK1NOX1SCD | |
| SCHEMBL30920741 | 0.88 | MAPK1 (0.33) | IKBKBSMN1; SMN2MAPK1 | |
| SCHEMBL30920798 | 0.88 | IKBKB (0.32) | IKBKBSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
| WO-2024081748-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | IKBKB 2262/4885SMN1; SMN2 375/4885MAPK1 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.